Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002850 · ClinicalTrials.gov registry record · Phase 3
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
A Phase 3 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT00002850 is a Phase 3 study that has completed, run by Gary Morrow. The registered enrollment target is 212 participants.
The verdict
NCT00002850, a Phase 3 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
Interventions
- DRUG ofloxacin
- DRUG ciprofloxacin
- DRUG 160 mg trimethoprim and 800 mg sulfamethoxazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 1997-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002850
The ClinicalTrials.gov registry entry for NCT00002850 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ofloxacin is the first listed.
NCT00002850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002850 about?
NCT00002850 is a clinical study titled "Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy". RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preve...
What is the current status of trial NCT00002850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 1997-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00002850?
The interventions under investigation include: ofloxacin (DRUG), ciprofloxacin (DRUG), 160 mg trimethoprim and 800 mg sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT00002850?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.